🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC99 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
2003 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
London, Oxford, Birmingham, Cardiff, Glasgow, Sheffield, Southampton
2025-11-19
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
Summit Therapeutics
Phase 3
600
Canterbury, London, Aberdeen, Edinburgh, Liverpool, Manchester
2025-11-18
Recruiting
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
NCT07186842Advanced Solid Cancers
BioNTech SE
Phase 1/2
245
Leeds, London, Manchester, Newcastle upon Tyne, Sutton
2025-11-18
Recruiting
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
NCT06887803Myelofibrosis (MF)
iOnctura
Phase 1/2
26
Boston, Belfast, London
2025-11-17
Active, closed
Consistency of Response With Rimegepant in Acute Treatment of Migraine
NCT06898047Migraine
Pfizer
Observational
250
London
2025-11-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
UCB Biopharma SRL
Phase 3
320
London, Salford
2025-11-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811NonSegmental Vitiligo
Incyte Corporation
Phase 3
250
Croydon, London, Sheffield, Walsall
2025-11-13
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627Ovarian Cancer
Incyte Corporation
Phase 2
160
London, Manchester Greater
2025-11-12
Recruiting
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
Hoffmann-La Roche
Phase 3
800
Bath, Birmingham, Edinburgh, Glasgow, London, Manchester, Oxford, Preston
2025-11-12
Recruiting
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
NCT07215585Large B-cell Lymphoma
AstraZeneca
Phase 3
420
Glasgow, Scotland, London, Newcastle upon Tyne, Nottingham
2025-11-11
Active, closed
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
NCT07216482Hyperlipidemia
Merck Sharp & Dohme LLC
Phase 3
996
Bristol, Yate, London, Corby
2025-11-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals
Phase 3
1,275
Brighton, Romford, Coventry, Glasgow, Leeds, London, Nottingham
2025-11-11
By invitation
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
NCT07156578Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc.
Phase 2
25
Birmingham, Cambridge, London
2025-11-10
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Liverpool, Dorchester, Wolverhampton, London, Sunderland
2025-11-10
Active, closed
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
NCT07073820Pulmonary Hypertension
Pfizer
Phase 2
42
London
2025-11-10
Recruiting
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
NCT07228364Autosomal Dominant Polycystic Kidney Disease
AstraZeneca
Phase 1
40
London
2025-11-10
Recruiting
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
NCT07259928Non-Proliferative Diabetic Retinopathy, Retinal Vein Occlusion
Annexin Pharmaceuticals AB
Phase 2
12
London
2025-11-07
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917Hidradenitis Suppurativa
Sanofi
Phase 2
208
London, Leeds
2025-11-06
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2/3
500
Glasgow, London, Sulton, Surrey
2025-11-05
Active, closed
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759Overweight, Obesity, Type 2 Diabetes
Novo Nordisk A/S
Phase 3
330
Liskeard, Newquay, Torquay, Bushey, London
2025-11-05
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Neovascular Age-related Macular Degeneration
AbbVie
Phase 3
561
Gloucester, London, Liverpool, Bristol, Sunderland
2025-11-05
Recruiting
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
NCT07189403Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo
Phase 1
40
London
2025-11-04
Recruiting
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
NCT07064122Haematologic Neoplasms
AstraZeneca
Phase 1
72
London, Manchester
2025-11-03
Recruiting
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
NCT06243731Cytomegalovirus (CMV), Kidney Disease, Kidney Failure
Takeda
Observational
10
Dorchester, Birmingham, London, Wrexham
2025-11-03
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Brighton, London, Taunton, Guildford, Cardiff
2025-11-03
Rows per page Showing 251–275 of 2003
Previous 9 10 11 12 13 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.